Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
68,578,543
-
Total 13F shares
-
58,125,270
-
Share change
-
+13,858,706
-
Total reported value
-
$1,633,269,044
-
Put/Call ratio
-
1.5%
-
Price per share
-
$28.10
-
Number of holders
-
112
-
Value change
-
+$360,165,764
-
Number of buys
-
72
-
Number of sells
-
50
Institutional Holders of Zentalis Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (ZNTL) as of Q2 2022
As of 30 Jun 2022,
Zentalis Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (ZNTL) was held by
112 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
58,125,270 shares.
The largest 10 holders included
Matrix Capital Management Company, LP, FMR LLC, VANGUARD GROUP INC, PRICE T ROWE ASSOCIATES INC /MD/, Avidity Partners Management LP, BlackRock Inc., STATE STREET CORP, TYBOURNE CAPITAL MANAGEMENT (HK) LTD, VIKING GLOBAL INVESTORS LP, and Decheng Capital Management III (Cayman), LLC.
This page lists
113
institutional shareholders reporting positions in this security
for the Q2 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.